As AI competition heats up, OpenEvidence’s rise shows investor confidence shifting toward purpose-built models designed for high-stakes industries like medicine.
The post OpenEvidence Raises $200M to Build a ‘ChatGPT for Medicine’ appeared first on TechRepublic.
